CTSOCytoSorbentsCTSO info
$1.03info0.98%24h
Global rank24784
Market cap$53.74M
Change 7d1.98%
YTD Performance-7.21%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    CytoSorbents (CTSO) Stock Overview

    Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

    CTSO Stock Information

    Symbol
    CTSO
    Address
    305 College Road EastPrinceton, NJ 08540United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.cytosorbents.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    732 329 8885

    CytoSorbents (CTSO) Price Chart

    -
    Value:-

    CytoSorbents Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.03
    N/A
    Market Cap
    $53.74M
    N/A
    Shares Outstanding
    52.17M
    N/A
    Employees
    198.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org